Login
$ORGO
$0.80 -$0.01 (0.86%) Live

$ORGO 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

CANTON, Mass., (November 5, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solut...

06 Aug 2026 8-K: Entry into a Material Definitive Agreement

Organogenesis Holdings Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG”) and Citizens JMP Securities, LLC (“Citizens” and, together with BTIG, the “Agents” and each, an “Agent...

06 Aug 2026 8-K: Results of Operations and Financial Condition

CANTON, Mass., (August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutio...

16 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

07 May 2026 8-K: Results of Operations and Financial Condition

CANTON, Mass., (May 7, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions ...

26 Feb 2026 8-K: Results of Operations and Financial Condition

CANTON, Mass., (February 26, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products f...

23 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

29 Dec 2025 8-K: Entry into a Material Definitive Agreement

THIS FIRST AMENDMENT TO LEASE (this “Amendment”) dated as of December 22, 2025, is entered into between Dan Road Associates, LLC, a Massachusetts limited liability company, with an address at c/o Draxxhall Management Corp., 300 Lighting ...

06 Nov 2025 8-K: Results of Operations and Financial Condition

CANTON, Mass., (November 6, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...

25 Sep 2025 8-K: Regulation FD Disclosure; Other Events

Change from Baseline WOMAC Pain Scale at 6 Months - Control-based Mean Imputation

07 Aug 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

CANTON, Mass., (August 7, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Su...

24 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

08 May 2025 8-K: Results of Operations and Financial Condition

CANTON, Mass., (May 8, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgi...

27 Mar 2025 8-K: Regulation FD Disclosure

FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectatio...

27 Feb 2025 8-K: Results of Operations and Financial Condition

CANTON, Mass., (February 27, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products f...

02 Dec 2024 8-K: Entry into a Material Definitive Agreement

THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 27, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and GN 2016 Family Trust u/a/d August 12, 2016 (the “Selling ...

22 Nov 2024 8-K: Entry into a Material Definitive Agreement; Other Events

Organogenesis Expands Manufacturing Capacity to Support Future Growth

13 Nov 2024 8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation +5 more

This SUBSCRIPTION AGREEMENT (the “Agreement”) is entered into this 12th day of November, 2024, by and among, Organogenesis Holdings Inc., a Delaware corporation (the “Company”), Avista Healthcare Partners III, L.P., a Delaware limited pa...

12 Nov 2024 8-K: Results of Operations and Financial Condition

CANTON, Mass., (November 12, 2024) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and...

08 Aug 2024 8-K: Results of Operations and Financial Condition

CANTON, Mass., (August 8, 2024) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Su...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support